论文部分内容阅读
AIM: To investigate the correlations of pre-treatment positron emission tomography-computer tomography(PET-CT) metabolic quantifiers with clinical data of unstratified gastric cancer(GC) patients.METHODS: Forty PET-CT scans utilising 18-fluorodeoxyglucose in patients who received no prior treatment were analysed. Analysis involved measurements of maximum and mean standardised uptake volumes(SUV), coefficient of variation(COV), metabolic tumour volumes and total lesion glycolysis of different thresholds above which the tumor volumes were identified. The threshold values were: SUV absolute value of 2.5, 30% of SUVmax, 40% of SUVmax,and liver uptake-based(marked 2.5, 30, 40 and liv,respectively). Clinical variables such as age, sex,clinical stage, performance index, weight loss, tumor histological type and grade, and CEA and CA19.9 levels were included in survival analysis. Patients received various treatment modalities appropriate to their disease stage and the outcome was defined by time to metastasis(TTM) and overall survival(OS). Clinical and metabolic parameters were evaluated by analysis ofvariance, receiver operating characteristics, univariate Kaplan-Meier, and multivariate Cox models. P < 0.05 was considered statistically significant.RESULTS: Significant differences were observed between initially disseminated and non-disseminated patients in mean SUV(6.05 vs 4.13, P = 0.008), TLG2.5(802 cm3 vs 226 cm3; P = 0.031), and TLG30(436 cm3 vs 247 cm3, P = 0.018). Higher COV was associated with poor tumour differentiation(0.47 for G3 vs0.28 for G1 and G2; P = 0.03). MTV2.5 was positively correlated to patient weight loss(< 5%, 5%-10%and > 10%: 40.4 cm3 vs 123.6 cm3 vs 181.8 cm3,respectively, P = 0.003). In multivariate Cox analysis,TLG30 was prognostic for OS(HR = 1.001, 95%CI:1.0009-1.0017; P = 0.047) for the whole group of patients. In the same model yet only including patients without initial disease dissemination TLG30(HR = 1.009,95%CI: 1.003-1.014; P = 0.004) and MTV2.5(HR = 1.02,95%CI: 1.002-1.036; P = 0.025) were prognostic for OS; for TTM TLG30 was the only significant prognostic variable(HR = 1.006, 95%CI: 1.001-1.012; P = 0.02).CONCLUSION: PET-CT in GC may represent a valuable diagnostic and prognostic tool that requires further evaluation in highly standardised environments such as randomised clinical trials.
AIM: To investigate the correlations of pre-treatment positron emission tomography-computer tomography (PET-CT) metabolic quantifiers with clinical data of unstratified gastric cancer (GC) patients. METHODS: Forty PET-CT scans utilising 18-fluorodeoxyglucose in patients who received no prior treatment were analysed. Analysis involved measurements of maximum and mean standardised uptake volumes (SUV), coefficient of variation (COV), metabolic volume volumes and total lesion glycolysis of different thresholds above which the tumor volumes were identified. The threshold values were: SUV absolute value of 2.5, 30% of SUVmax, 40% of SUVmax, and liver uptake-based (marked 2.5, 30, 40 and liv, respectively). Clinical variables such as age, sex, clinical stage, performance index, weight loss , tumor histological type and grade, and CEA and CA19.9 levels were included in survival analysis. Patients received various treatment modalities appropriate to their disease stage and the outcome was defined by tim e to metastasis (TTM) and overall survival (OS). Clinical and metabolic parameters were evaluated by analysis of variances, receiver operating characteristics, univariate Kaplan-Meier, and multivariate Cox models. P <0.05 wasīvesperson significant.RESULTS: Significant differences were observed between initially disseminated and non-disseminated patients in mean SUV (6.05 vs 4.13, P = 0.008), TLG 2.5 (802 cm3 vs 226 cm3; P = 0.031), and TLG30 (436 cm3 vs 247 cm3, Higher COV was associated with poor tumor differentiation (0.47 for G3 vs 0.28 for Gl and G2; P = 0.03). MTV 2.5 was positively correlated to patient weight loss (<5%, 5% -10% and> 10% : 40.4 cm3 vs 123.6 cm3 vs 181.8 cm3, respectively, P = 0.003). In multivariate Cox analysis, TLG30 was prognostic for OS (HR = 1.001, 95% CI: 1.0009-1.0017; P = 0.047) for the whole group of patients . In the same model yet only including patients without initial disease dissemination TLG30 (HR = 1.009, 95% CI: 1.003-1.014; P = 0.004) and(HR = 1.02, 95% CI: 1.002-1.036; P = 0.025) were prognostic for OS; for TTM TLG30 was the only significant prognostic variable (HR = 1.006, 95% CI: 1.001-1.012; ). CONCLUSION: PET-CT in GC may represent a valuable diagnostic and prognostic tool that requires further evaluation in highly standardized environments such as randomized clinical trials.